The interferon landscape along the respiratory tract impacts the severity of COVID-19

Abstract

Severe coronavirus disease 2019 (COVID-19) is characterized by overproduction of immune mediators, but the role of interferons (IFNs) of the type I (IFN-I) or type III (IFN-III) families remains debated. We scrutinized the production of IFNs along the respiratory tract of COVID-19 patients and found that high levels of IFN-III, and to a lesser extent IFN-I, characterize the upper airways of patients with high viral burden but reduced disease risk or severity. Production of specific IFN-III, but not IFN-I, members denotes patients with a mild pathology and efficiently drives the transcription of genes that protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In contrast, compared to subjects with other infectious or noninfectious lung pathologies, IFNs are overrepresented in the lower airways of patients with severe COVID-19 that exhibit gene pathways associated with increased apoptosis and decreased proliferation. Our data demonstrate a dynamic production of IFNs in SARS-CoV-2-infected patients and show IFNs play opposing roles at distinct anatomical sites.

Cited by papers we hold 5

• The development of COVID-19 treatment · 2023
  No notice
• SEACells infers transcriptional and epigenomic cellular states from single-cell genomics data · 2023
  No notice
• NULISA: a proteomic liquid biopsy platform with attomolar sensitivity and high multiplexing · 2023
  No notice
• SARS-CoV-2-Specific Immune Response and the Pathogenesis of COVID-19 · 2022
  No notice
• The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies · 2022
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.